Pila Pharma AB (OSTO:PILA) Total Equity: kr14.65 Mil (As of Dec. 2025)


OSTO:PILA Pila Pharma AB OSTO:PILA
49 GF Score
Price kr1.24
GF Value kr1.83
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pila Pharma AB Total Equity?

Pila Pharma AB OSTO:PILA -1.20% 49 Total Equity is kr14.65 Mil as of Dec. 2025. GuruFocus rates OSTO:PILA with a GF Score™ of 49/100 and a GF Value™ of kr1.83 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Pila Pharma AB's total equity for the quarter that ended in Dec. 2025 was kr14.65 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Pila Pharma AB Total Equity Historical Data

* Premium members only.

The historical data trend for Pila Pharma AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pila Pharma AB Total Equity Chart

Pila Pharma AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 30.30 9.53 6.66 5.26 14.65

Pila Pharma AB Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.66 2.58 5.26 1.16 14.65
OSTO:PILA
49GF Score
Pila Pharma AB OSTO:PILA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pila Pharma AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Pila Pharma AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=16.218-1.573
=14.65

Pila Pharma AB's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=16.218-1.573
=14.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr14.65 Mil mean?
Pila Pharma AB (OSTO:PILA) has a Total Equity of kr14.65 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Pila Pharma AB and its competitors.
Is Pila Pharma AB's Total Equity too high?
Pila Pharma AB's current Total Equity is kr14.65 Mil. Overall, Pila Pharma AB has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's Total Equity compare to VRTX and REGN?
Pila Pharma AB's Total Equity of kr14.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pila Pharma AB and its competitors. Pila Pharma AB's current Total Equity is kr14.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Pila Pharma AB (OSTO:PILA) is currently considered Significantly Undervalued. The stock's GF Value™ is kr1.83, compared to a current price of kr1.24 — trading 32.5% below its estimated fair value. The current Total Equity is kr14.65 Mil. Pila Pharma AB's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pila Pharma AB (OSTO:PILA), the current Total Equity is kr14.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pila Pharma AB (OSTO:PILA) Overvalued in 2026?

Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued. The current stock price of kr1.24 is trading 32.5% below its estimated GF Value™ of kr1.83. GuruFocus considers Pila Pharma AB to be Significantly Undervalued.

Key valuation signals for OSTO:PILA:

  • Total Equity: kr14.65 Mil
  • GF Value™: kr1.83 vs. price of kr1.24 (32.5% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the OSTO:PILA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pila Pharma AB Business Description

Address Norra Vallgatan 72, Malmo, SWE, 211 21
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
49GF Score

Get the complete analysis for OSTO:PILA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.24
Price
kr1.83
GF Value